Ratings by Morgan Stanley (Judah Frommer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/10/2026 | Lakefront Biotherapeutics | LKFT | New Coverage | Equalweight (N/A) |
30.81 (30.01) |
-2.6% | Details | |
| 6/30/2026 | Evommune Inc | EVMN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2026 | Engene Holdings Inc. | ENGN | Downgrade | Underweight (Equalweight) |
1.75 (1.82) |
4% | Details | |
| 6/2/2026 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/26/2026 | Avalyn Pharma | AVLN | New Coverage | Overweight (N/A) |
28.41 (28.30) |
-0.39% | Details | |
| 5/15/2026 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2026 | Evommune Inc | EVMN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Trevi Therapeutics | TRVI | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/16/2026 | Kalaris | KLRS | New Coverage | Overweight (N/A) |
5.82 (4.38) |
-24.74% | Details | |
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Immix Biopharma, Inc. | IMMX | New Coverage | Overweight (N/A) |
8.81 (10.25) |
16.35% | Details | |
| 3/18/2026 | Trevi Therapeutics | TRVI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2026 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2026 | Belite Bio, Inc, ADR | BLTE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2026 | Agomab Therapeutics | AGMB | New Coverage | Overweight (N/A) |
16.02 (12.04) |
-24.84% | Details | |
| 2/26/2026 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2026 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2026 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/19/2026 | Evommune Inc | EVMN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2026 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2026 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2026 | Belite Bio, Inc, ADR | BLTE | New Coverage | Overweight (N/A) |
159.27 (150.08) |
-5.77% | Details | |
| 12/8/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/1/2025 | Evommune Inc | EVMN | New Coverage | Overweight (N/A) |
19.41 (12.14) |
-37.45% | Details | |
| 11/14/2025 | Trevi Therapeutics | TRVI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | 4D Molecular Therapeutics | FDMT | Upgrade | Equalweight (Underweight) |
10.51 (10.99) |
4.57% | Details | |
| 11/5/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/29/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2025 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2025 | Trevi Therapeutics | TRVI | New Coverage | Overweight (N/A) |
7.32 (19.07) |
160.52% | Details | |
| 8/7/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/23/2025 | Abivax | ABVX | Upgrade | Overweight (Equalweight) |
10.00 (136.65) |
1266.5% | Details | |
| 7/3/2025 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Overweight (N/A) |
13.76 (28.49) |
107.05% | Details | |
| 7/3/2025 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
44.44 (115.77) |
160.51% | Details | |
| 6/5/2025 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/1/2025 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2025 | Mural Oncology | MURA | Downgrade | Equalweight (Overweight) |
3.83 (2.04) |
-46.74% | Details | |
| 3/20/2025 | Celldex Therapeutics | CLDX | New Coverage | Overweight (N/A) |
19.89 (35.35) |
77.73% | Details | |
| 3/20/2025 | Blueprint Medicines | BPMC | New Coverage | Equalweight (N/A) |
89.59 (129.46) |
44.5% | Details | |
| 3/20/2025 | Abivax | ABVX | New Coverage | Equalweight (N/A) |
6.80 (10.00) |
47.06% | Details | |
| 3/14/2025 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/21/2024 | 4D Molecular Therapeutics | FDMT | New Coverage | Underweight (N/A) |
8.67 (10.51) |
21.22% | Details | |
| 11/21/2024 | Apellis Pharmaceuticals | APLS | New Coverage | Equalweight (N/A) |
28.99 (41.03) |
41.53% | Details | |
| 11/15/2024 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
10.67 (9.89) |
-7.31% | Details | |
| 11/8/2024 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2024 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2024 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/8/2024 | Bicara Therapeutics Inc | BCAX | New Coverage | Overweight (N/A) |
25.16 (27.76) |
10.33% | Details | |
| 8/2/2024 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2024 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/4/2024 | Mural Oncology | MURA | New Coverage | Overweight (N/A) |
4.73 (3.83) |
-19.03% | Details | |
| 3/7/2024 | ProKidney Corp. | PROK | New Coverage | Equalweight (N/A) |
1.76 (1.62) |
-7.95% | Details | |
| 3/7/2024 | Galapagos NV | GLPG | New Coverage | Equalweight (N/A) |
34.51 (27.73) |
-19.65% | Details | |
| 3/7/2024 | Arcellx Inc. | ACLX | New Coverage | Overweight (N/A) |
69.64 (115.07) |
65.24% | Details |
